bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 2059: Identification of novel paclitaxel sensitivity genes via lentiviral CRISPR/Cas9 screening in haploid human cells
Authors: Hunt Jessica R. , Lawo Steffen , Walter David , Nett Isabelle , Yarker Joanne , Cross Benedict C S , Moore Jonathan D. 
Published: July 2016

Abstract
Some cancers lack clearly druggable driver mutations and might also have too few neo-antigen generating mutations to provoke a tumor-specific immune response, even in the presence of antibodies targeting immune checkpoint mechanisms. Synthetic lethal/non-oncogene addiction represents an alternative approach to the therapy of such cancers, as exemplified by the recent approval of olaparib.
RNA interference has identified several putative synthetic lethal targets, but few, if any, of these have have withstood vigorous validation. The recent application of RNA-guided gene editing to mammalian cells offers new prospects for target identification. The complete ablation of gene expression, which this technology permits allows the identification of targets that have no phenotype when partially depleted by RNA interference.
Horizon has recently established a capability for CRISPR-Cas9 KO screening. Screens are performed by transducing a pool of cells with a complex lentiviral library. Next generation sequencing is then used to identify which sgRNAs are accumulating or being depleted from the population. As there are multiple sgRNAs per gene, we can rank genes for their likelihood of having a phenotype under the conditions used in the screen. Our proof-of-principle small molecule resistance and sensitivity screens using both whole-genome libraries and custom subset libraries have successfully identified previously published hits and also yielded novel hits.
Horizon has also developed a fully haploid cell line (eHAP), which has the potential to provide additional clarity in genetic screening. To evaluate the power of CRISPR-Cas9 KO screening in haploid cells, we have used our screening platform to identify genes required for survival in low doses of paclitaxel. Whole-genome screening using the GeCKOv2 library identified three kinesins amongst the most prominent of the hits whose depletion sensitised cells to this microtubule stabilising agent. Intriguingly, two of these kinesins, KIF2A and KIF2C are thought to destabilise mitotic microtubules, providing an attractive explanation for the synthetic lethality.
We will also present results from a second genome-wide CRISPR KO screen in haploid cells to identify genes required for survival under glucose starvation. Prominent hits included components of the electron transport chain and the tuberous sclerosis complex.
Citation Format: Jessica R. Hunt, Steffen Lawo, David Walter, Isabelle Nett, Joanne Yarker, Benedict C S Cross, Jonathan D. Moore. Identification of novel paclitaxel sensitivity genes via lentiviral CRISPR/Cas9 screening in haploid human cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2059.
Abstract 2066: Albumin-binding doxorubicin prodrug selectively activated by radiation-induced apoptotic tumor cells
Authors: Chung Seung Woo , Kim Kwangmeyung , Kim Seong Who , Kim In-San , Kim Sang Yoon , Byun Youngro 
Published: July 2016

Abstract
Despite the well-recognized potent anticancer effect of doxorubicin, the clinical use of doxorubicin is limited due to its dose-dependent toxicity. In this study, a novel drug delivery technology fundamentally different from the conventional tumor-targeting approaches was employed to improve the therapeutic index of doxorubicin. The prepared doxorubicin prodrug, EMC-DEVD-S-DOX, has two distinct features for effective tumor targeting: EPR effect-mediated passive targeting of tumor and extended plasma half-life by in situ albumin binding, and radiation-induced apoptosis targeting. The prodrug comprises of two important functional molecules: first, a maleimide group that allows in situ binding of the prodrug to the circulating albumin after intravenous administration; second, a DEVD motif that plays a crucial role in the activation of the prodrug through caspase-3-mediated cleavage in the apoptotic tumor cells that are exposed to radiation. As a result, EMC-DEVD-S-DOX showed a prolonged plasma half-life with selective accumulation within the tumor tissue, and was only activated and released free doxorubicin when combined with radiotherapy, thereby showing excellent synergistic effect. Our suggested drug delivery strategy completely relies on the anatomical feature of tumor vasculatures and the upregulated caspase-3 after exposure to radiation. In this reason, the genomic variations of tumor cells are unlikely to influence the efficacy of the prodrug. Considering that the conventional active tumor targeting approach is seriously challenged by the intratumor heterogeneity, EMC-DEVD-S-DOX could be an outstanding alternative for an effective cancer treatment.
Citation Format: Seung Woo Chung, Kwangmeyung Kim, Seong Who Kim, In-San Kim, Sang Yoon Kim, Youngro Byun. Albumin-binding doxorubicin prodrug selectively activated by radiation-induced apoptotic tumor cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2066.
Abstract 2067: Attacking prostate cancer with a prodrug-doped cellular Trojan horse
Authors: Brennen Nathaniel , Levy Oren , Han Edward , Rosen David Marc , Musabeyezu Juliet , Safaee Helia , Ranganath Sudhir , Ngai Jessica , Heinelt Martina , Billett Sandrine , Bhowmick Neil , Denmeade Samuel , Karp Jeffrey , Isaacs John 
Published: July 2016

Abstract
Prostate cancer is the second leading cause of cancer-related deaths in American men. Despite considerable advances in prostate cancer research, there is a major need for a systemic delivery platform that efficiently targets anti-cancer drugs to sites of disseminated prostate cancer while minimizing host toxicity. Human mesenchymal stem cells (MSCs) are excellent candidates for cell-based drug delivery since they display tropism towards cancer sites and clinical studies have demonstrated that hundreds of millions of allogeneic human MSCs can be safely administered intravenously without adverse effects in a variety of pathological settings. Furthermore, we have previously documented that MSCs can be detected in radical prostatectomy tissue from men with prostate cancer. In this proof-of-concept study, human MSCs were loaded with poly(lactic-co-glycolic acid) (PLGA) microparticles (MPs) encapsulating the macromolecule G114, a thapsigargin-based prostate specific antigen (PSA)-activated prodrug. G114-loaded MPs were successfully internalized by MSCs without impacting MSC viability, followed by sustained release of G114 as an intact prodrug from loaded cells. Moreover, G114 released from G114 MP-loaded MSCs is selectively toxic to the PSA-secreting prostate cancer cell line, LNCaP. Finally, G114 MP-loaded MSCs inhibited tumor growth when co-inoculated with CWR22 prostate cancer xenografts, suggesting that cell-based delivery of G114 does not compromise potency of the prodrug in vitro or in vivo. We envision that this MSC-based platform may be developed into an effective, systemic ‘Trojan Horse’ therapy for the targeted delivery of therapeutic agents to sites of metastatic prostate cancer.
Citation Format: Nathaniel Brennen, Oren Levy, Edward Han, David Marc Rosen, Juliet Musabeyezu, Helia Safaee, Sudhir Ranganath, Jessica Ngai, Martina Heinelt, Sandrine Billett, Neil Bhowmick, Samuel Denmeade, Jeffrey Karp, John Isaacs. Attacking prostate cancer with a prodrug-doped cellular Trojan horse. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2067.
Abstract 2077: Carbonate prodrugs derived from triterpenoids with high cytotoxic activity
Authors: Dzubak Petr , Burianova Renata , Michalova Martina , Liskova Barbora , Urban Milan , Sarek Jan , Galandakova Adela , Ulrichova Jitka , Hajduch Marian 
Published: July 2016

Abstract
Number of active anticancer compounds failed in the drug development due to unfavorable pharmacological properties. Design of pro-drugs is plausible approach to improve drug-like properties of biologically active compounds. Betulinic acid is a well-known representative of triterpenes, which possess a moderate cytotoxic activity and high selectivity towards the tumor cells. However, its pharmacological properties, particularly solubility and bioavailability, are poor. In order to improve pharmacology of betulinic acid derivatives, we have synthesized and tested activities of above 40 carbonate based prodrugs. We have developed methods for activation of “pro-drug” derivatives of betulinic acid by primary rat hepatocytes. Cytotoxicity of pro-drugs and activated metabolites was measured on the sensitive tumor cell line CCRF-CEM (human T-lymphoblastic leukemia). We have identified 21 prodrugs &gt;10 times more cytotoxic to CCRF-CEM cells after pre-incubation with rat hepatocytes. The best candidate pro-drug showed &gt;100 fold increase of cytotoxicity due to metabolic activation and it was cytotoxic to cancer cells in sub-micromolar concentrations. Our concept and predicted mechanisms of pro-drug activation were verified by HPLC-MS/MS where the pro-drugs and corresponding active compounds were identified and quantified. For the most active derivatives we have tested ADME characteristics and in vivo pharmacokinetics which showed significantly improved drug-like properties. Analysis of anti-cancer activities of the pro-drugs is currently being performed. This work was supported by grants LF_2015_031 and by the National Sustainability Program (LO1304).
Citation Format: Petr Dzubak, Renata Burianova, Martina Michalova, Barbora Liskova, Milan Urban, Jan Sarek, Adela Galandakova, Jitka Ulrichova, Marian Hajduch. Carbonate prodrugs derived from triterpenoids with high cytotoxic activity. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2077.
Abstract 209: The effect of heme influx on initiation and tumorigenesis of NSCLC
Authors: Sohoni Sagar , Alam Md Maksudul , Vidal Chantal , Hooda Jagmohan , Zhang Li 
Published: July 2016

Abstract
Heme is a central molecule for mitochondrial function and for all processes involved in oxygen utilization. Heme serves as a prosthetic group or as a cofactor for a number of oxidative phosphorylation enzymes and other oxygen-utilizing hemoproteins. Heme also directly regulates the synthesis, translocation and assembly of these enzyme complexes. Most, if not all, human cells can synthesize and uptake heme from the circulation. A number of epidemiological studies have shown that high heme intake is associated with increased risk of cancer, including lung cancer. Recent studies carried out in our lab showed intensified mitochondrial respiration and increased levels of heme and hemoproteins in non-small-cell lung cancer (NSCLC) cells. Together, these experimental and epidemiological studies strongly suggest that heme is an “oncometabolite.” To assess the status of heme metabolism in cancer cells, we performed a series of experiments in NSCLC cells and compared the results with an immortalized normal lung cell line, HBEC30KT. We used Zinc protoporphyrin, an analogue of heme to measure the level of heme uptake. We found that heme uptake as well as heme synthesis are significantly elevated in all NSCLC cells compared to HBEC. The rate of heme degradation was also measured in these cell lines. Previously, our lab demonstrated that lowering intracellular heme levels selectively decreases oxygen consumption in NSCLC cells and inhibits cell migration and colony formation. Experiments are underway to test ways to alter intracellular heme availability and characterize their effects on NSCLC tumor growth and metastasis.
Citation Format: Sagar Sohoni, Md Maksudul Alam, Chantal Vidal, Jagmohan Hooda, Li Zhang. The effect of heme influx on initiation and tumorigenesis of NSCLC. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 209.
Abstract 2153: ATP7B is a promising therapeutic target for uterine leiomyosarcoma
Authors: Kakuda Mamoru 
Published: July 2016

Abstract
Objective
Resistance to platinum drugs remains a significant problem in uterine leiomyosarcoma (LMS). We investigated the role of ATP7B in the resistance to platinum drugs in LMS using both in vitro and in vivo models.
Methods
The expression of the typical platinum transporters (MDR1, MRP2, ATP7A, and ATP7B) was examined in LMS cell lines using Western blotting analysis. ATP7A expression was investigated by immunohistochemistry (IHC) using clinical samples of LMS. IC50 values to cisplatin were measured in SK-LMS cells, SK-LMS-ATP7B-suppressed cell line (SK-LMS-7B cells), which permanently transfected PRS ATP7B shRNA vector. We established xenografted mice by inoculating SK-LMS cells and SK-LMS-7B cells, and examined in vivo platinum sensitivity with cisplatin for both tumors. This study was approved by the Institutional Review Board and the Ethics Committee of the Osaka University Hospital (approval #10302, approved on March 11, 2011).
Results
The expression of ATP7B was identified in the SK-LMS cells. ATP7B expression was identified in 70% (14/20) of the LMS clinical samples using IHC. The IC50-values to cisplatin improved from 17 mM to 4.3 mM after the suppression of ATP7B in SK-LMS-7B cells. A significant anti-tumor effect of cisplatin was observed in SK-LMS-7B xenografted mice than in SK-LMS xenografted mice. We also identified CuSO4 as an preferentially inhibitor of ATP7B in vitro.
Conclusion
ATP7B is associated with platinum resistance. CuSO4 acting as an inhibitor of ATP7B can be a therapeutic target for LMS.
Citation Format: Mamoru Kakuda. ATP7B is a promising therapeutic target for uterine leiomyosarcoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2153.
Abstract 2155: Acquired tamoxifen resistance sensitises breast cancer cells to bisphosphonates
Authors: Lymperatou Dionysia , Smith Christopher , Jiang Wen Guo , Evans Bronwen , Hiscox Stephen 
Published: July 2016

Abstract
Acquisition of resistance to endocrine therapies is a major limiting factor to their clinical effectiveness, resulting in disease relapse and poor prognosis. This may be due in part to the observations that acquired resistance to agents such as tamoxifen is accompanied by a gain in aggressive cellular features likely to promote disease spread and survival at metastatic sites. Bisphosphonates (BPs) are potent antiresorptive drugs used to treat osteoporosis and bone metastasis. Recent evidence also suggests that these agents may possess anti-tumour properties independently of their action on osteoclasts in a range of different tumours including breast cancers resulting in suppression of proliferation and migration and an induction of apoptosis. Here we have explored the potential of the bisphosphonate, zoledronic acid (ZOL) to suppress the aggressive phenotype of acquired endocrine-resistant breast cancer models versus their endocrine-sensitive counterparts.
ER+, endocrine-sensitive MCF7 cells and their highly-proliferative, ER+, tamoxifen-resistant (‘TamR’) counterparts were exposed to increasing concentrations of ZOL (1-160μM) for 3 days and changes in growth determined by MTT assay and cell counting. Immunohistochemical analysis of Ki67 confirmed cell growth effects whilst cell cycle analysis was performed using FACS and propidium iodide. Changes in signalling pathways were investigated by Western blotting.
The proliferative capacity of TamR cells was greatly suppressed by ZOL in a dose dependent manner in contrast to MCF7, where the effect was minimal (IC50 ± SD: 30 ± 4 μM (TamR) versus 150 ± 15 μM (MCF7); p&lt;0.05). This was confirmed with Ki67 analysis which showed a reduction in Ki67 positivity of 40% (TamR) versus 25% (MCF7); p&lt;0.05. ZOL treatment of TamR cells resulted in a significant loss of cells in G1 phase and an accumulation of the cells in S phase. ZOL treatment of TamR cells also resulted in loss of AKT activity, whilst AKT was unaffected in MCF7 cells.
Our data suggests that acquisition of resistance to tamoxifen confers a sensitivity to BPs where treatment of resistant cells with agents such as zoledronic acid results in suppression of proliferation and modulation of AKT signalling. These data suggest that BPs may exert direct anti-tumour effects on breast cancers which have relapsed on endocrine treatment.
Citation Format: Dionysia Lymperatou, Christopher Smith, Wen Guo Jiang, Bronwen Evans, Stephen Hiscox. Acquired tamoxifen resistance sensitises breast cancer cells to bisphosphonates. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2155.
Abstract 216: The effect of UCP2 upregulation on cellular redox status and mitochondrial respiration
Authors: Sreedhar Annapoorna , Zhao Yunfeng 
Published: July 2016

Abstract
Uncoupling protein 2 (UCP2) is a mitochondrial protein present in the inner mitochondrial membrane. They belong to the family of anion mitochondrial carriers. UCP2 are thought to have natural antioxidant effect by attenuating the generation of superoxides.
Since cancer cells exhibit elevated oxidative stress, they can effectively adapt to this situation by upregulating UCP2. As a matter of fact, UCP2 is overexpressed in many forms of cancer including prostate, breast, lung and head & neck. Not surprising, our early studies demonstrate that knockout of UCP2 suppresses skin tumor formation in a multistage skin carcinogenesis model.
The purpose of this study was to detect the impact of UCP2's upregulation on mitochondrial redox status and mitochondrial respiration, using the well characterized tumor promotion model, JB6p+ cells. Our results have demonstrated that UCP2 overexpression enhanced protein expression and activity levels of manganese superoxide dismutase (MnSOD), a mitochondrial-resident enzyme that governs the egression of superoxides. To assess the impact of MnSOD upregulation on mitochondrial redox status, levels of superoxides and hydrogen peroxides were detected. Our results indicated that MnSOD upregulation maintained steady flow of hydrogen peroxides originating from mitochondria. We further examined the effect of UCP2 upregulation-induced MnSOD expression on mitochondrial respiration and glycolytic rate. In agreement with our data, cells overexpressing UCP2 had significantly higher oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). In conclusion, our data suggests that UCP2 promotes carcinogenesis via decreasing superoxide generation whereas promoting hydrogen peroxide production via elevating MnSOD. Collectively, our results support the hypothesis that enhanced UCP2 expression sustains metabolic switch in cancer cells.
Citation Format: Annapoorna Sreedhar, Yunfeng Zhao. The effect of UCP2 upregulation on cellular redox status and mitochondrial respiration. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 216.
Abstract 217: Mitochondrial reprogramming regulated cancer pathway in triple negative breast cancer
Authors: Park Jun H. , Vithayathil Sajna , Wu Danli , Putluri Vasanta , Sung Pi-Lin , Tsouko Efrosini , Bhat Vadiraja B. , Coarfa Cristian , Frigo Daniel E. , Lewis Michael T. , Sreekumar Arun , Yotnda Patricia , Creighton Chad J. , Putluri Nagireddy , Wong Lee-Jun C. , Kaipparettu Benny A. 
Published: July 2016

Abstract
Compared to other subtypes of tumors, triple negative breast cancers (TN BCa) currently suffer from limited knowledge on its etiology and treatment options. Transmitochondrial cybrids (cybrid) and multiple OMICs approaches were used to understand mitochondrial reprogramming and mitochondria-regulated cancer pathways in TN BCa. Analysis of cybrids and established BCa cell lines showed that metastatic TN BCa maintain high levels of ATP through fatty acid β-oxidation and activate Src oncoprotein by its autophosphorylation. Inhibition and induction of β-oxidation including the shRNA mediated knockdown strategies, and analysis of patient derived xenograft (PDX) models confirmed the role of mitochondrial β-oxidation in Src activation and metastasis. Analysis of BCa clinical data further reaffirmed the role of mitochondrial β-oxidation in Src regulation and their significance in BCa metastasis. This study is innovative in showing the mitochondrial reprogramming mediated regulation of a major cancer pathway by its post-translation modification.
Citation Format: Jun H. Park, Sajna Vithayathil, Danli Wu, Vasanta Putluri, Pi-Lin Sung, Efrosini Tsouko, Vadiraja B. Bhat, Cristian Coarfa, Daniel E. Frigo, Michael T. Lewis, Arun Sreekumar, Patricia Yotnda, Chad J. Creighton, Nagireddy Putluri, Lee-Jun C. Wong, Benny A. Kaipparettu. Mitochondrial reprogramming regulated cancer pathway in triple negative breast cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 217.